Meeting
2016 ASCO Annual Meeting
HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
Authors
Kathy Miller
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Kathy Miller , Javier Cortes , Sara A. Hurvitz , Ian E. Krop , Debu Tripathy , Sunil Verma , Michelle Dionne , Karen Campbell , Joseph G. Reynolds , Thomas J. Wickham , Istvan Molnar , Denise A. Yardley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02213744
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS631)
DOI
10.1200/JCO.2016.34.15_suppl.TPS631
Abstract #
TPS631
Poster Bd #
110a
Abstract Disclosures
Similar Posters
First Author: Kathy Miller
Poster
2016 ASCO Annual Meeting
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.
First Author: Yutaka Yamamoto
Poster
2016 ASCO Annual Meeting
SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).
First Author: Hope S. Rugo
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop